You can buy or sell AGTC and other stocks, options, ETFs, and crypto commission-free!
Applied Genetic Technologies Corp. engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. Read More The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.
52 Week High
52 Week Low
Applied Genetic Technologies (AGTC) Q3 Earnings and Revenues Surpass Estimates
Applied Genetic Technologies (AGTC) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of a loss of $0.54 per share.
Yahoo FinanceMay 7
Applied Genetic Technologies: Fiscal 3Q Earnings Snapshot
ALACHUA, Fla. (AP) _ Applied Genetic Technologies Corp. (AGTC) on Tuesday reported fiscal third-quarter net income of $11.5 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Alachua, Florida-based company said it had net income of 63 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 54 cents per share. The biotechnology company posted revenue of $21.3 million in the ...
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2019
GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended March 31, 2019. "Completing enrollment in the dose escalation portion of our Phase 1/2 trial in patients with achromatopsia due to mutations in the CNGB3 gene and the expansi...
-$0.58 per share
-$0.49 per share